Murthi Mukunthan, Prasath Naveen, Memdani Anisha, Sivasubramanian Dhiran, Attanasio Steve, Dhar Gaurav, Jolly Neeraj, Vij Aviral
Department of Cardiology, John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois.
Department of Internal Medicine, University of Florida, Gainesville, Florida.
Coron Artery Dis. 2025 Sep 1;36(6):467-473. doi: 10.1097/MCA.0000000000001488. Epub 2024 Dec 19.
Limited data is available regarding in-hospital outcomes of patients undergoing high-risk percutaneous coronary intervention (HR-PCI) with Impella with and without a prior history of coronary artery bypass grafting (CABG).
We performed a retrospective study from the Nationwide Inpatient Sample from year 2016 to 2020. We identified patients who underwent Impella and percutaneous coronary intervention on the same day and excluded those with cardiogenic shock. Subsequently, we stratified them into those with and without prior CABG.
During the study period, 18 925 patients underwent HR-PCI. Among these, 2043 (10.8%) patients had prior CABG. Patients without prior CABG had a higher percentage of acute coronary syndrome at presentation (62.7 vs 56.1%, P = 0.008). The proportion of females was significantly higher in those without prior CABG (32.4 vs 21.7%, P < 0.001). On multivariate analysis, there was no statistically significant difference in the in-hospital mortality (5.8% in CABG vs 8.5% in non-CABG, P = 0.52). Patients without prior CABG had higher rates of acute kidney injury, major bleeding, and blood transfusions. There were no significant differences in rates of cardiac arrest, ventricular arrhythmias, acute stroke, coronary dissections, and coronary perforations. Those without prior CABG had a longer duration of hospitalization (6.8 vs 9.3 days, P < 0.001) and higher hospital charges ($292 267 vs $322 206, P < 0.035).
Our study highlights that a history of previous CABG does not increase the risk of in-hospital mortality in patients undergoing Impella-assisted HR-PCI but is associated with reduced rates of complications.
关于接受高风险经皮冠状动脉介入治疗(HR-PCI)并使用Impella的患者,有无冠状动脉旁路移植术(CABG)既往史的院内结局数据有限。
我们对2016年至2020年全国住院患者样本进行了一项回顾性研究。我们确定了同一天接受Impella和经皮冠状动脉介入治疗的患者,并排除了心源性休克患者。随后,我们将他们分为有和无CABG既往史两组。
在研究期间,18925例患者接受了HR-PCI。其中,2043例(10.8%)患者有CABG既往史。无CABG既往史的患者就诊时急性冠状动脉综合征的比例更高(62.7%对56.1%,P = 0.008)。无CABG既往史的患者中女性比例显著更高(32.4%对21.7%,P < 0.001)。多因素分析显示,院内死亡率无统计学显著差异(CABG组为5.8%,非CABG组为8.5%,P = 0.52)。无CABG既往史的患者急性肾损伤、大出血和输血发生率更高。心脏骤停、室性心律失常、急性卒中、冠状动脉夹层和冠状动脉穿孔发生率无显著差异。无CABG既往史的患者住院时间更长(6.8天对9.3天,P < 0.001),住院费用更高(292267美元对322206美元,P < 0.035)。
我们的研究强调,既往CABG史不会增加接受Impella辅助HR-PCI患者的院内死亡风险,但与并发症发生率降低相关。